7.97
price up icon3.51%   0.27
after-market Dopo l'orario di chiusura: 7.97
loading
Precedente Chiudi:
$7.70
Aprire:
$7.73
Volume 24 ore:
208.91K
Relative Volume:
1.08
Capitalizzazione di mercato:
$162.03M
Reddito:
$66.59M
Utile/perdita netta:
$-104.93M
Rapporto P/E:
-1.6101
EPS:
-4.95
Flusso di cassa netto:
$-96.48M
1 W Prestazione:
+6.98%
1M Prestazione:
+26.71%
6M Prestazione:
+42.58%
1 anno Prestazione:
-40.74%
Intervallo 1D:
Value
$7.705
$8.228
Intervallo di 1 settimana:
Value
$7.2327
$8.228
Portata 52W:
Value
$4.09
$17.23

Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile

Name
Nome
Enanta Pharmaceuticals Inc
Name
Telefono
617 607 0800
Name
Indirizzo
4 KINGSBURY AVENUE, WATERTOWN, MA
Name
Dipendente
131
Name
Cinguettio
@EnantaPharma
Name
Prossima data di guadagno
2025-02-10
Name
Ultimi documenti SEC
Name
ENTA's Discussions on Twitter

Confronta ENTA con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ENTA
Enanta Pharmaceuticals Inc
7.97 162.03M 66.59M -104.93M -96.48M -4.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-08-09 Downgrade JP Morgan Neutral → Underweight
2023-08-08 Downgrade Jefferies Buy → Hold
2022-12-09 Iniziato H.C. Wainwright Buy
2022-07-06 Aggiornamento Evercore ISI In-line → Outperform
2022-06-01 Aggiornamento Evercore ISI Underperform → In-line
2021-10-07 Iniziato Jefferies Buy
2021-09-09 Iniziato SVB Leerink Mkt Perform
2021-01-29 Aggiornamento JP Morgan Underweight → Neutral
2020-11-24 Iniziato Evercore ISI Underperform
2020-08-28 Ripresa ROTH Capital Buy
2020-08-26 Iniziato Piper Sandler Overweight
2020-07-27 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2020-03-17 Aggiornamento Robert W. Baird Neutral → Outperform
2019-11-22 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2019-09-26 Downgrade JP Morgan Neutral → Underweight
2019-05-24 Iniziato Wolfe Research Outperform
2019-04-23 Aggiornamento Berenberg Hold → Buy
2018-12-13 Iniziato Berenberg Hold
2018-06-06 Iniziato ROTH Capital Buy
2018-02-08 Downgrade JP Morgan Overweight → Neutral
2018-01-02 Downgrade RBC Capital Mkts Outperform → Sector Perform
2017-11-21 Reiterato RBC Capital Mkts Outperform
2017-09-15 Iniziato RBC Capital Mkts Outperform
2017-07-11 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
2016-04-28 Downgrade JMP Securities Mkt Outperform → Mkt Perform
2016-02-09 Reiterato Barclays Underweight
2015-10-23 Downgrade Barclays Equal Weight → Underweight
2015-10-23 Aggiornamento JMP Securities Mkt Perform → Mkt Outperform
Mostra tutto

Enanta Pharmaceuticals Inc Borsa (ENTA) Ultime notizie

pulisher
Jun 13, 2025

Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com

Jun 13, 2025
pulisher
Jun 12, 2025

ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com

Jun 12, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga

Jun 11, 2025
pulisher
Jun 11, 2025

AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance

Jun 11, 2025
pulisher
Jun 10, 2025

(ENTA) Proactive Strategies - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 04, 2025

Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus

Jun 03, 2025
pulisher
Jun 03, 2025

Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK

Jun 03, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace

May 27, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus

May 27, 2025
pulisher
May 27, 2025

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus

May 27, 2025
pulisher
May 26, 2025

Enanta Pharmaceuticals discovers new 17β-HSD13 inhibitors - BioWorld MedTech

May 26, 2025
pulisher
May 24, 2025

Enanta Pharmaceuticals’ SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com Nigeria

May 24, 2025
pulisher
May 22, 2025

Enanta to present RSV drug study results at ESPID 2025 By Investing.com - Investing.com South Africa

May 22, 2025
pulisher
May 22, 2025

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting - BioSpace

May 22, 2025
pulisher
May 22, 2025

Enanta to present RSV drug study results at ESPID 2025 - Investing.com

May 22, 2025
pulisher
May 19, 2025

(ENTA) On The My Stocks Page - news.stocktradersdaily.com

May 19, 2025
pulisher
May 18, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - simplywall.st

May 18, 2025
pulisher
May 15, 2025

Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

May 15, 2025
pulisher
May 14, 2025

Citizens JMP Increases Enanta (ENTA) Price Target to $23 | ENTA Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

ENANTA PHARMACEUTICALS INC SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Enanta stock price target raised to $23 by JMP - Investing.com Canada

May 14, 2025
pulisher
May 14, 2025

Enanta price target raised to $23 from $21 at Citizens JMP - TipRanks

May 14, 2025
pulisher
May 13, 2025

Enanta (ENTA) Reports Revenue Miss and Advances Drug Development Programs | ENTA Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Enanta Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks

May 13, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 - BioSpace

May 12, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals Reports Q2 Loss of $1.06 Per Share, Beati - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Enanta Pharmaceuticals: Fiscal Q2 Earnings Snapshot - News-Times

May 12, 2025
pulisher
May 08, 2025

(ENTA) Trading Report - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - MSN

May 07, 2025
pulisher
May 05, 2025

11 Best Breakout Stocks to Buy According to Analysts - Insider Monkey

May 05, 2025
pulisher
Apr 27, 2025

JMP Securities maintains Enanta stock with $21 target - MSN

Apr 27, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 23, 2025

(ENTA) Investment Report - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com

Apr 08, 2025
pulisher
Apr 08, 2025

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire

Apr 08, 2025
pulisher
Apr 08, 2025

Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan

Apr 08, 2025
pulisher
Apr 07, 2025

(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Apr 07, 2025
pulisher
Apr 05, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Enanta Pharmaceuticals Inc Azioni (ENTA) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Enanta Pharmaceuticals Inc Azioni (ENTA) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
Kieffer Tara Lynn
Chief Product Strategy Officer
Dec 06 '24
Sale
8.06
2,283
18,401
29,305
Luu Brendan
Chief Business Officer
Dec 06 '24
Sale
8.06
2,283
18,401
36,047
Rottinghaus Scott T.
Chief Medical Officer
Dec 06 '24
Sale
8.06
866
6,980
17,918
Or Yat Sun
Chief Scientific Officer
Dec 06 '24
Sale
8.06
2,591
20,883
369,109
MELLETT PAUL J
Chief Fin. & Admin Officer
Dec 06 '24
Sale
8.06
2,591
20,883
91,710
Luly Jay R.
President and CEO
Dec 06 '24
Sale
8.06
5,142
41,445
801,638
Rottinghaus Scott T.
Chief Medical Officer
Jul 15 '24
Option Exercise
8.99
5,375
48,321
27,092
Rottinghaus Scott T.
Chief Medical Officer
Jul 15 '24
Sale
17.08
5,375
91,805
21,717
Rottinghaus Scott T.
Chief Medical Officer
Jul 11 '24
Sale
15.07
4,299
64,786
23,988
Rottinghaus Scott T.
Chief Medical Officer
Jul 12 '24
Sale
15.04
2,271
34,156
21,717
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.23
price up icon 0.63%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Capitalizzazione:     |  Volume (24 ore):